SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Amylin Pharmaceuticals, Inc. Release: BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes